Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by Bryan, Garnier & Co in a report issued on Monday. They currently have a GBX 6,900 ($84.10) price objective on the biopharmaceutical company’s stock. Bryan, Garnier & Co’s target price would suggest a potential upside of 35.85% from the company’s current price.

A number of other brokerages have also issued reports on SHP. Goldman Sachs Group Inc. restated a “buy” rating and set a GBX 6,300 ($76.78) target price on shares of Shire PLC in a research report on Wednesday, October 12th. Deutsche Bank AG restated a “buy” rating and set a GBX 6,200 ($75.56) target price on shares of Shire PLC in a research report on Wednesday, October 12th. HSBC lowered shares of Shire PLC to a “hold” rating and lowered their target price for the stock from GBX 5,400 ($65.81) to GBX 5,250 ($63.99) in a research report on Monday, September 26th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire PLC in a research report on Friday, September 23rd. Finally, Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research report on Wednesday, September 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eighteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of GBX 5,907.50 ($72.00).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) traded down 1.32% during midday trading on Monday, hitting GBX 5079.00. 1,312,836 shares of the stock were exchanged. The firm has a 50-day moving average price of GBX 5,014.25 and a 200-day moving average price of GBX 4,619.00. The stock’s market cap is GBX 34.68 billion. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

The firm also recently declared a dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 8th were issued a GBX 3.51 ($0.04) dividend. This represents a yield of 0.07%. The ex-dividend date of this dividend was Thursday, September 8th.

In other Shire PLC news, insider Dominic Blakemore purchased 133 shares of the stock in a transaction on Friday, September 30th. The stock was bought at an average price of GBX 5,010 ($61.06) per share, for a total transaction of £6,663.30 ($8,121.02).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.